| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$681,877 | ROE | — |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $2.4M | Trading Days | 1360 |
| 52W High | 1.35 |
| 52W Low | 0.31 |
| % Off High | −75.30% |
| YTD | 7.07% | 1Y | −10.00% |
| 3Y | −61.72% | 5Y | −77.80% |
| Since incept. (ann.) | −35.36% |
| Ann. Volatility (1Y) | 448.86% | Ann. Volatility (3Y) | 317.32% |
| Sharpe (1Y) | 1.81 | Sharpe (3Y) | 1.26 |
| Max Drawdown (1Y) | −75.30% | Max Drawdown (3Y) | −75.93% |
| Beta (3Y, vs SPY) | −0.25 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CLDI | Calidi Biotherapeutics, Inc. | $2.1M | — |
| PHGE | BiomX Inc. | $2.0M | 0.0 |
| CELZ | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | $2.9M | — |
| VIVS | VivoSim Labs, INC. | $1.4M | — |
| APTOF | Aptose Biosciences Inc. | $4.3M | — |
| LIMN | Liminatus Pharma, Inc. | $4.6M | — |
| PMCB | PharmaCyte Biotech, Inc. | $6.3M | 0.2 |
| CVM | CEL SCI CORP | $10.0M | — |
| BCLI | BRAINSTORM CELL THERAPEUTICS INC. | $11.0M | — |
| INAB | IN8BIO, INC. | $11.7M | — |
| INTS | INTENSITY THERAPEUTICS, INC. | $12.4M |
| CERO | CERO THERAPEUTICS HOLDINGS, INC. | $437,590 | — |
